NCT03083821View on ClinicalTrials.gov

A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 16, 2017

Primary Completion Date

December 19, 2017

Study Completion Date

December 19, 2017

Conditions
Hepatitis B Virus
Interventions
DRUG

Baraclude

Specified dose on specified day

Trial Locations (1)

1920071

Local Institution, Hachioji-shi

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY